Pharma Mar, S.A. (BME:PHM)

Market Cap	1.42B
Revenue (ttm)	174.86M
Net Income (ttm)	26.13M
Shares Out	17.57M
EPS (ttm)	1.49
PE Ratio	54.25
Forward PE	34.98
Dividend	0.65 (0.85%)
Ex-Dividend Date	Jun 12, 2024

Volume	21,959
Average Volume	65,809
Open	80.80
Previous Close	80.80
Day's Range	79.60 - 81.90
52-Week Range	27.98 - 105.80
Beta	0.06
RSI	50.30
Earnings Date	Apr 25, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.